{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_metadata=all&_sort=-registeredInterest", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "isPartOf" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "type" : "http://purl.org/linked-data/api/vocab#ListEndpoint"}
    , "items" : [{"_about" : "http://data.parliament.uk/resources/1010153", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1010153/answer", "answerText" : {"_value" : "<p>This information is not available by local authority.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-22T17:42:15.717Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Eating Disorders"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 October 2018 to Question 177617 on Eating disorders, if he will list the 70 new or extended community services providing specialist community-based care for eating disorders that are open or in development by the local authority in which they are based.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "192754"}
    , {"_about" : "http://data.parliament.uk/resources/1012292", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1012292/answer", "answerText" : {"_value" : "<p>The Government supports the principle that creators should be fairly rewarded for their work whilst ensuring that we continue to encourage investment in new content and innovative services. We are engaging with our European partners to achieve these aims during Trilogue negotiations on this Directive.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3980", "label" : {"_value" : "Biography information for Mr Sam Gyimah"}
        }
        , "answeringMemberConstituency" : {"_value" : "East Surrey"}
        , "answeringMemberPrinted" : {"_value" : "Mr Sam Gyimah"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T14:50:26.217Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Copyright: EU Action"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to the Trilogue process in relation to the EU Directive on Copyright in the Digital Single Market, whether the Government plans to support the inclusion of provisions to ensure that creators receive fair remuneration for the use of their works.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "194603"}
    , {"_about" : "http://data.parliament.uk/resources/1012293", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1012293/answer", "answerText" : {"_value" : "<p>The Government has considered this issue in the context of its Brexit analysis. It has concluded that the reciprocal arrangements between UK Collective Management Organisations (CMOs) and EU CMOs to collect royalties from EU countries and distribute to creators in the UK are private commercial agreements which are expected to continue after the UK has exited the European Union.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3980", "label" : {"_value" : "Biography information for Mr Sam Gyimah"}
        }
        , "answeringMemberConstituency" : {"_value" : "East Surrey"}
        , "answeringMemberPrinted" : {"_value" : "Mr Sam Gyimah"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T15:43:32.79Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Copyright: EU Countries"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential effect of the UK leaving the EU on the reciprocal relationships the UK has with the EU that enable collective management organisations to collect royalties from EU countries and distribute to creators in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "194604"}
    , {"_about" : "http://data.parliament.uk/resources/1012294", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1012294/answer", "answerText" : {"_value" : "The UK will always be a European country that advocates for cultural diversity as part of its global identity and is committed to continuing its contribution to and support of European culture. The Government has been clear that will be explore participation in any successor programme to Creative Europe. Where EU funding programmes are to the UK and EU's joint advantage, we want to discuss continued participation as part of the negotiations. Ultimately, the decision on which programmes are in the UK\u2019s interests will be decided as part of the future partnership negotiations, which are ongoing."}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4115", "label" : {"_value" : "Biography information for Margot James"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stourbridge"}
        , "answeringMemberPrinted" : {"_value" : "Margot James"}
        , "dateOfAnswer" : {"_value" : "2018-11-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-27T19:18:35.98Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "10"}
      , "answeringDeptShortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "answeringDeptSortName" : {"_value" : "Digital, Culture, Media and Sport"}
      , "date" : {"_value" : "2018-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Arts: EU Grants and Loans"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Digital, Culture, Media and Sport, whether the Government plans to remain part of Creative Europe after the current funding period concludes in 2020.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "194605"}
    , {"_about" : "http://data.parliament.uk/resources/1016320", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1016320/answer", "answerText" : {"_value" : "<p>The agreement of an implementation period will ensure that access to medicines and medical devices continues, and patient safety is maintained, in both the United Kingdom and European Union markets.<\/p><p> <\/p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be the UK competent authority during this period.<\/p><p> <\/p><p>For medical devices, CE marks are assigned by notified bodies (rather than competent authorities such as the MHRA), and during the implementation period UK notified bodies will continue to conduct third-party conformity assessment in the UK, and the results of these tests will continue to be used and recognised for both the UK and EU markets.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2018-12-03", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-03T18:29:34.66Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-28", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medicines and Healthcare products Regulatory Agency"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the transition period set out in the agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union, whether the Medicines and Healthcare Products Regulatory Agency will retain its status as a competent authority; and whether existing CE marks assigned under that agency will be valid from 29 March 2019 until the end of that transition period.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "196736"}
    , {"_about" : "http://data.parliament.uk/resources/1020404", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1020404/answer", "answerText" : {"_value" : "<p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.<\/p><p> <\/p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.<\/p><p> <\/p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.<\/p><p> <\/p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2018-12-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "199327"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-10T14:12:25.46Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-12-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medicines and Healthcare products Regulatory Agency"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 03 December 2018 to Question 196736 on Medicines and Healthcare Products Regulatory Agency (MHRA), and with reference to the transition period set out in the Agreement on the Withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union, if the MHRA will be recognised as an EU competent authority under the EU (a) Medical Devices Directive, (b) in-vitro diagnostic medical devices, and (c) Medical Devices Regulation during the period covered by the Agreement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "199325"}
    , {"_about" : "http://data.parliament.uk/resources/1020405", "AnsweringBody" : [{"_value" : "Department for Exiting the European Union "}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1020405/answer", "answerText" : {"_value" : "<p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as an EU competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.<\/p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.<\/p><p><strong><\/strong><br><br><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3977", "label" : {"_value" : "Biography information for Chris Heaton-Harris"}
        }
        , "answeringMemberConstituency" : {"_value" : "Daventry"}
        , "answeringMemberPrinted" : {"_value" : "Chris Heaton-Harris"}
        , "dateOfAnswer" : {"_value" : "2018-12-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-10T15:48:34.12Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "203"}
      , "answeringDeptShortName" : {"_value" : "Exiting the European Union "}
      , "answeringDeptSortName" : {"_value" : "Exiting the European Union "}
      , "date" : {"_value" : "2018-12-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medicines and Healthcare products Regulatory Agency"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Exiting the European Union, pursuant to the Answer of 03 December 2018 to Question 196736 on Medicines and Healthcare Products Regulatory Agency (MHRA) and with reference to the transition period set out in the Agreement on the Withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union, if the MHRA will be recognised as an EU competent authority under EU Regulations (a) Medical Devices Directive, (b) in-vitro diagnostic medical devices, and (c) Medical Devices Regulation during that period.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "199326"}
    , {"_about" : "http://data.parliament.uk/resources/1020408", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1020408/answer", "answerText" : {"_value" : "<p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.<\/p><p> <\/p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.<\/p><p> <\/p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.<\/p><p> <\/p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2018-12-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "199325"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-10T14:12:25.523Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-12-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Equipment: UK Notified Bodies"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 03 December 2018 to Question 196736 on Medicines and Healthcare Products Regulatory Agency (MHRA), whether the Department's response refers to (a) UK notified bodies licensed by the MHRA and (b) UK notified bodies that have also secured notified body status in other EU states.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "199327"}
    , {"_about" : "http://data.parliament.uk/resources/1022956", "AnsweringBody" : [{"_value" : "Department for Education"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1022956/answer", "answerText" : {"_value" : "<p>Demand for children\u2019s services is associated with a number of factors, including deprivation. The most deprived local authorities (LAs) have more looked after children (per 10,000 17 year olds), and these rates have grown faster than the least deprived LAs.<\/p><p>In preparation for the Spending Review, to help ensure decisions are based on the best available evidence, the government is working with the sector to develop a sharper and more granular picture of demand for children\u2019s services.<\/p><p>We are also working with Ministry of Housing, Communities and Local Government as part of the Government\u2019s Fair Funding Review of relative needs and resources, where new, up-to-date formulas are being developed to ensure funding distribution to councils is based on the best available evidence.<\/p><p>We welcome the contributions from the sector in this area, including Newton Europe\u2019s Making Sense (2018) report and the Association of Directors of Children\u2019s Services' continuing research reports, Safeguarding Pressures (2018).<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2018-12-13", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-13T14:41:48.833Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "60"}
      , "answeringDeptShortName" : {"_value" : "Education"}
      , "answeringDeptSortName" : {"_value" : "Education"}
      , "date" : {"_value" : "2018-12-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Children: Social Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Education, what recent assessment he has made of the correlation between deprivation and demand for children\u2019s services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "200581"}
    , {"_about" : "http://data.parliament.uk/resources/1024789", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1024789/answer", "answerText" : {"_value" : "<p>Public Health England (PHE) has run a number of \u2018Be Clear on Cancer\u2019 campaigns to help improve early detection of cancer including ovarian cancer. In 2014 PHE ran a pilot regional ovarian cancer campaign in the North West of England. In 2017, PHE ran a pilot campaign in the East and West Midlands which focussed on a range of abdominal symptoms, such as diarrhoea, bloating and discomfort that can be indicative of a number of cancers, including ovarian cancer. NHS England has invested over £200 million between 2017 and 2019, supporting Cancer Alliances to accelerate diagnosis and enhance quality of life.<\/p><p> <\/p><p>Staffordshire clinical commissioning groups commission diagnostic services for ovarian cancer fully in line with National Institute for Health and Care Excellence guidelines across the whole sustainability and transformation partnership.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-12-18", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-18T17:04:54.847Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-12-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Ovarian Cancer: Staffordshire"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) increase early diagnosis rates for ovarian cancer and (b) increase access to treatment for ovarian cancer in specialist centres in Staffordshire.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1436", "label" : {"_value" : "Biography information for Paul Farrelly"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle-under-Lyme"}
      , "tablingMemberPrinted" : [{"_value" : "Paul Farrelly"}
      ], "uin" : "202081"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&tablingMemberConstituency=Newcastle-under-Lyme&_properties=tablingMember.label,answer.questionFirstAnswered,answer.attachment.fileName,answer.groupedQuestionUIN,date&_sort=-registeredInterest", "page" : 0, "startIndex" : 1, "totalResults" : 759, "type" : "http://purl.org/linked-data/api/vocab#Page"}
}